1
|
Shi KN, Li PB, Su HX, Gao J, Li HH. MK-886 protects against cardiac ischaemia/reperfusion injury by activating proteasome-Keap1-NRF2 signalling. Redox Biol 2023; 62:102706. [PMID: 37098317 PMCID: PMC10149391 DOI: 10.1016/j.redox.2023.102706] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Revised: 04/09/2023] [Accepted: 04/18/2023] [Indexed: 04/27/2023] Open
Abstract
Oxidative stress is considered a key factor contributing to the initiation and development of cardiac injury following ischaemia‒reperfusion (I/R). Arachidonate 5-lipoxygenase (ALOX5) is a rate-limiting enzyme for leukotriene biosynthesis. MK-886 is an inhibitor of ALOX5 that exhibits anti-inflammatory and antioxidant activities. However, the significance of MK-886 in preventing I/R-mediated cardiac injury and the underlying mechanism remain unclear. Cardiac I/R model was produced by ligation/release of the left anterior descending artery. MK-886 (20 mg/kg) was administered intraperitoneally into mice at 1 and 24 h before I/R. Our results indicated that MK-886 treatment significantly attenuated I/R-mediated cardiac contractile dysfunction and decreased the infarct area, myocyte apoptosis, and oxidative stress accompanied with reduction of Kelch-like ECH-associated protein 1 (keap1) and upregulation of nuclear factor erythroid 2-related factor 2 (NRF2). Conversely, administration of the proteasome inhibitor epoxomicin and NRF2 inhibitor ML385 greatly abrogated MK-886-mediated cardioprotection after I/R injury. Mechanistically, MK-886 enhanced the expression of the immunoproteasome subunit β5i, which interacted with keap1 and enhanced its degradation, leading to activation of the NRF2-dependent antioxidant response and improvement of mitochondrial fusion-fission balance in the I/R-treated heart. In summary, our present findings indicated that MK-886 could protect the heart against I/R injury and highlight that MK-886 may represent a promising therapeutic candidate for preventing ischaemic disease.
Collapse
Affiliation(s)
- Kai-Na Shi
- Department of Emergency Medicine, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China
| | - Pang-Bo Li
- Department of Emergency Medicine, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China
| | - Hui-Xiang Su
- Department of Emergency Medicine, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China
| | - Jing Gao
- Department of Emergency Medicine, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China
| | - Hui-Hua Li
- Department of Emergency Medicine, Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, China.
| |
Collapse
|
2
|
Zamani M, Prabhakaran MP, Varshosaz J, Mhaisalkar PS, Ramakrishna S. Electrosprayed Montelukast/poly (lactic-co-glycolic acid) particle based coating: A new therapeutic approach towards the prevention of in-stent restenosis. Acta Biomater 2016; 42:316-328. [PMID: 27397493 DOI: 10.1016/j.actbio.2016.07.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Revised: 06/06/2016] [Accepted: 07/06/2016] [Indexed: 01/18/2023]
Abstract
UNLABELLED Drug-eluting stents (DESs), have shown promising results in prevention of in-stent restenosis after percutaneous coronary intervention (PCI). The elevated level of leukotrienes (LTs) detected in injured arteries after PCI, together with the potential role of LTs in inflammatory cascades and structural alterations in arterial wall provides the rationale for development of therapeutic strategies for prevention of in-stent restenosis using LTs receptor antagonists. Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties, which has been used for treatment of various diseases. Here, we report on the fabrication of MK/PLGA particles by electrospraying, aiming towards the development of particle based coating of DESs. The electrosprayed particles incorporated with 3% and 6% w/w MK exhibited fairly spherical shape with smooth surfaces and narrow size distribution. Sustained release of MK for up to 40days was obtained for both formulations, with higher initial burst release and drug release rate for the particles with higher drug loading. The LTD4 induced proliferation and migration of human coronary artery smooth muscle cells (HCASMCs) by 35% and 85%, respectively, which was substantially antagonized using MK incorporated particles. Nevertheless, MK antagonism preserved the normal proliferation and migration of human coronary artery endothelial cells (HCAECs). Moreover, MK antagonism inhibited the LTD4 induced phenotypic transition of HCASMCs from contractile to synthetic type. The electrosprayed MK-PLGA particles can be employed as a coating for DESs to inhibit the formation of neointimal hyperplasia responsible for in-stent restenosis, yet preserve the healing rate of the stented vessel. STATEMENT OF SIGNIFICANT Montelukast (MK) is a selective cysLT1 receptor antagonist, with anti-inflammatory and anti-proliferative properties. The LTD4 induced proliferation and migration of human coronary artery smooth muscle cells by 35% and 85%, respectively, which was substantially antagonized using MK incorporated particles. MK antagonism preserved the normal proliferation and migration of human coronary artery endothelial cells. The MK antagonism inhibited the phenotypic transition of human coronary artery smooth muscle cells from contractile to synthetic one induced by LTD4. The electrosprayed MK-PLGA particles can be employed as coating for DESs to inhibit formation of neointimal hyperplasia, responsible for in-stent restenosis.
Collapse
Affiliation(s)
- Maedeh Zamani
- Department of Mechanical Engineering, National University of Singapore, 2 Engineering Drive 3, Singapore 117576, Singapore.
| | - Molamma P Prabhakaran
- Department of Mechanical Engineering, National University of Singapore, 2 Engineering Drive 3, Singapore 117576, Singapore.
| | - Jaleh Varshosaz
- Department of Pharmaceutics, Novel Drug Delivery Systems Research Centre and School of Pharmacy, Isfahan University of Medical Sciences, Isfahan 81746-73461, Iran.
| | - Priyadarshini S Mhaisalkar
- School of Materials and Science Engineering, Nanyang Technological University, 50 Nanyang Avenue, Singapore 639798, Singapore.
| | - Seeram Ramakrishna
- Department of Mechanical Engineering, National University of Singapore, 2 Engineering Drive 3, Singapore 117576, Singapore.
| |
Collapse
|
3
|
Stanke-Labesque F, Pépin JL, Gautier-Veyret E, Lévy P, Bäck M. Leukotrienes as a molecular link between obstructive sleep apnoea and atherosclerosis. Cardiovasc Res 2013; 101:187-93. [DOI: 10.1093/cvr/cvt247] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
4
|
Yu Z, Ricciotti E, Miwa T, Liu S, Ihida-Stansbury K, Landersberg G, Jones PL, Scalia R, Song W, Assoian RK, FitzGerald GA. Myeloid cell 5-lipoxygenase activating protein modulates the response to vascular injury. Circ Res 2013; 112:432-40. [PMID: 23250985 PMCID: PMC3565603 DOI: 10.1161/circresaha.112.300755] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2012] [Accepted: 12/17/2012] [Indexed: 11/16/2022]
Abstract
RATIONALE Human genetics have implicated the 5-lipoxygenase enzyme in the pathogenesis of cardiovascular disease, and an inhibitor of the 5-lipoxygenase activating protein (FLAP) is in clinical development for asthma. OBJECTIVE Here we determined whether FLAP deletion modifies the response to vascular injury. METHODS AND RESULTS Vascular remodeling was characterized 4 weeks after femoral arterial injury in FLAP knockout mice and wild-type controls. Both neointimal hyperplasia and the intima/media ratio of the injured artery were significantly reduced in the FLAP knockouts, whereas endothelial integrity was preserved. Lesional myeloid cells were depleted and vascular smooth muscle cell (VSMC) proliferation, as reflected by bromodeoxyuridine incorporation, was markedly attenuated by FLAP deletion. Inflammatory cytokine release from FLAP knockout macrophages was depressed, and their restricted ability to induce VSMC migration ex vivo was rescued with leukotriene B(4). FLAP deletion restrained injury and attenuated upregulation of the extracellular matrix protein, tenascin C, which affords a scaffold for VSMC migration. Correspondingly, the phenotypic modulation of VSMC to a more synthetic phenotype, reflected by morphological change, loss of α-smooth muscle cell actin, and upregulation of vascular cell adhesion molecule-1 was also suppressed in FLAP knockout mice. Transplantation of FLAP-replete myeloid cells rescued the proliferative response to vascular injury. CONCLUSIONS Expression of lesional FLAP in myeloid cells promotes leukotriene B(4)-dependent VSMC phenotypic modulation, intimal migration, and proliferation.
Collapse
MESH Headings
- 5-Lipoxygenase-Activating Proteins/deficiency
- 5-Lipoxygenase-Activating Proteins/genetics
- 5-Lipoxygenase-Activating Proteins/metabolism
- Animals
- Bone Marrow Transplantation
- Cell Movement
- Cell Proliferation
- Cells, Cultured
- Cysteine/metabolism
- Disease Models, Animal
- Endothelial Cells/metabolism
- Endothelial Cells/pathology
- Femoral Artery/enzymology
- Femoral Artery/injuries
- Femoral Artery/pathology
- Genotype
- Hyperplasia
- Inflammation Mediators/metabolism
- Leukotriene B4/metabolism
- Leukotrienes/metabolism
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Muscle, Smooth, Vascular/enzymology
- Muscle, Smooth, Vascular/immunology
- Muscle, Smooth, Vascular/injuries
- Muscle, Smooth, Vascular/pathology
- Myeloid Cells/enzymology
- Myeloid Cells/immunology
- Myeloid Cells/transplantation
- Myocytes, Smooth Muscle/enzymology
- Myocytes, Smooth Muscle/immunology
- Myocytes, Smooth Muscle/pathology
- Neointima
- Phenotype
- Tenascin/metabolism
- Time Factors
- Vascular Cell Adhesion Molecule-1/metabolism
- Vascular System Injuries/enzymology
- Vascular System Injuries/genetics
- Vascular System Injuries/immunology
- Vascular System Injuries/pathology
- Vascular System Injuries/prevention & control
Collapse
Affiliation(s)
- Zhou Yu
- The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Emanuela Ricciotti
- The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Takashi Miwa
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Shulin Liu
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Kaori Ihida-Stansbury
- The Institute for Medicine and Engineering, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Gavin Landersberg
- The Department of Physiology, Temple University, Philadelphia, PA, 19140
| | - Peter L. Jones
- The Institute for Medicine and Engineering, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Rosario Scalia
- The Department of Physiology, Temple University, Philadelphia, PA, 19140
| | - Wenchao Song
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Richard K. Assoian
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| | - Garret A. FitzGerald
- The Institute for Translational Medicine and Therapeutics, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
- The Department of Pharmacology, University of Pennsylvania, 3400 Civic Center Boulevard, Philadelphia, PA, 19104
| |
Collapse
|
5
|
Farias S, Frey LC, Murphy RC, Heidenreich KA. Injury-related production of cysteinyl leukotrienes contributes to brain damage following experimental traumatic brain injury. J Neurotrauma 2010; 26:1977-86. [PMID: 19886806 DOI: 10.1089/neu.2009.0877] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The leukotrienes belong to a family of biologically active lipids derived from arachidonate that are often involved in inflammatory responses. In the central nervous system, a group of leukotrienes, known as the cysteinyl leukotrienes, is generated in brain tissue in response to a variety of acute brain injuries. Although the exact clinical significance of this excess production remains unclear, the cysteinyl leukotrienes may contribute to injury-related disruption of the brain-blood barrier and exacerbate secondary injury processes. In the present study, the formation and role of cysteinyl leukotrienes was explored in the fluid percussion injury model of traumatic brain injury in rats. The results showed that levels of the cysteinyl leukotrienes were elevated after fluid percussion injury with a maximal formation 1 hour after the injury. Neutrophils contributed to cysteinyl leukotriene formation in the injured brain hemisphere, potentially through a transcellular biosynthetic mechanism. Furthermore, pharmacological reduction of cysteinyl leukotriene formation after the injury, using MK-886, resulted in reduction of brain lesion volumes, suggesting that the cysteinyl leukotrienes play an important role in traumatic brain injury.
Collapse
Affiliation(s)
- Santiago Farias
- Department of Pharmacology, University of Colorado at Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA
| | | | | | | |
Collapse
|
6
|
Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, Feldman L, Bäck M. Leukotriene Receptor Antagonism and the Prevention of Extracellular Matrix Degradation During Atherosclerosis and In-Stent Stenosis. Arterioscler Thromb Vasc Biol 2009; 29:518-24. [DOI: 10.1161/atvbaha.108.181750] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Hanna Hlawaty
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Marie-Paule Jacob
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Liliane Louedec
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Didier Letourneur
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Charles Brink
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Jean-Baptiste Michel
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Laurent Feldman
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| | - Magnus Bäck
- From the INSERM U698 (H.H., M.-P.J., L.L., D.L., C.B., J.-B.M., L.F., M.B.), University of Paris 13 (H.H., D.L.), University of Paris 7 (M.-P.J., C.B., J.-B.M., L.F.), and the Department of Cardiology (L.F., M.B.), Bichat Hospital, Paris, France; and the Center for Molecular Medicine (M.B.), Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
7
|
Di Gennaro A, Kenne E, Wan M, Soehnlein O, Lindbom L, Haeggström JZ. Leukotriene B
4
‐ induced changes in vascular permeability are mediated by neutrophil release of heparin‐binding protein (HBP/CAP37/azurocidin). FASEB J 2009; 23:1750-7. [DOI: 10.1096/fj.08-121277] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Affiliation(s)
- Antonio Di Gennaro
- Department of Medical Biochemistry and BiophysicsDivision of Chemistry 2Karolinska InstitutetStockholmSweden
| | - Ellinor Kenne
- Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden
| | - Min Wan
- Department of Medical Biochemistry and BiophysicsDivision of Chemistry 2Karolinska InstitutetStockholmSweden
| | - Oliver Soehnlein
- Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden
| | - Lennart Lindbom
- Department of Physiology and PharmacologyKarolinska InstitutetStockholmSweden
| | - Jesper Z. Haeggström
- Department of Medical Biochemistry and BiophysicsDivision of Chemistry 2Karolinska InstitutetStockholmSweden
| |
Collapse
|
8
|
Tennant GM, Wadsworth RM, Kennedy S. PAR-2 mediates increased inflammatory cell adhesion and neointima formation following vascular injury in the mouse. Atherosclerosis 2008; 198:57-64. [DOI: 10.1016/j.atherosclerosis.2007.09.043] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/17/2007] [Revised: 09/21/2007] [Accepted: 09/27/2007] [Indexed: 11/29/2022]
|
9
|
Lenon GB, Xue CCL, Story DF, Thien FCK, McPhee S, Li CG. Inhibition of release of inflammatory mediators in primary and cultured cells by a Chinese herbal medicine formula for allergic rhinitis. Chin Med 2007; 2:2. [PMID: 17302969 PMCID: PMC1805751 DOI: 10.1186/1749-8546-2-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2006] [Accepted: 02/15/2007] [Indexed: 11/12/2022] Open
Abstract
Background We demonstrated that a Chinese herbal formula, which we refer to as RCM-101, developed from a traditional Chinese medicine formula, reduced nasal and non-nasal symptoms of seasonal allergic rhinitis (SAR). The present study in primary and cultured cells was undertaken to investigate the effects of RCM-101 on the production/release of inflammatory mediators known to be involved in SAR. Methods Compound 48/80-induced histamine release was studied in rat peritoneal mast cells. Production of leukotriene B4 induced by the calcium ionophore A23187 was studied in porcine neutrophils using an HPLC assay and lipopolysaccharide-stimulated prostaglandin E2 production was studied in murine macrophage (Raw 264.7) cells by immune-enzyme assay. Expression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) was determined in Raw 264.7 cells, using western blotting techniques. Results RCM-101 (1–100 μg/mL) produced concentration-dependent inhibition of compound 48/80-induced histamine release from rat peritoneal mast cells and of lipopolysaccharide-stimulated prostaglandin E2 release from Raw 264.7 cells. Over the range 1 – 10 μg/mL, it inhibited A23187-induced leukotriene B4 production in porcine neutrophils. In addition, RCM-101 (100 μg/mL) inhibited the expression of COX-2 protein but did not affect that of COX-1. Conclusion The findings indicate that RCM-101 inhibits the release and/or synthesis of histamine, leukotriene B4 and prostaglandin E2 in cultured cells. These interactions of RCM-101 with multiple inflammatory mediators are likely to be related to its ability to reduce symptoms of allergic rhinitis.
Collapse
Affiliation(s)
- George B Lenon
- The RMIT Chinese Medicine Research Group, RMIT University, Plenty Road, Bundoora 3083, Australia
| | - Charlie CL Xue
- The RMIT Chinese Medicine Research Group, RMIT University, Plenty Road, Bundoora 3083, Australia
| | - David F Story
- The RMIT Chinese Medicine Research Group, RMIT University, Plenty Road, Bundoora 3083, Australia
| | - Frank CK Thien
- Alfred Hospital & Monash University, Commercial Road, Melbourne 3004, Australia
| | - Sarah McPhee
- The Natural Products Research Group, School of Medical Sciences, RMIT University, Plenty Road, Bundoora 3083, Australia
| | - Chun G Li
- The RMIT Chinese Medicine Research Group, RMIT University, Plenty Road, Bundoora 3083, Australia
| |
Collapse
|
10
|
Stanke-Labesque F, Hardy G, Caron F, Cracowski JL, Bessard G. Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats. Br J Pharmacol 2003; 140:186-94. [PMID: 12967948 PMCID: PMC1574003 DOI: 10.1038/sj.bjp.0705405] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
(1) Long-term treatment of rats with Nomega-nitro-l-arginine methyl ester (l-NAME) induces hypertension associated with inflammatory and vascular changes. Leukotrienes are proinflammatory vasoactive products that are suspected to be involved in the pathogenesis of hypertension. We investigated, in rats chronically treated with l-NAME, the involvement of leukotrienes in the in vivo regulation of blood pressure and the in vitro contraction elicited by noradrenaline in isolated aorta. (2) Rats were randomly assigned to four groups and orally treated for 3 weeks with l-NAME (1 mg ml-1), l-NAME (1 mg ml-1) plus the leukotriene biosynthesis inhibitor MK-886 (0.1 mg ml-1), MK-886 (0.1 mg ml-1) alone or vehicle (Methocel, 0.1%). All the drugs were added to the drinking fluid. (3) The mean arterial blood pressure (MABP) increased significantly in l-NAME-treated rats (173.3+/-9.4 mmHg (n=25)) vs Methocel-treated rats (110.7+/-4.8 mmHg (n=11), P<0.001). Chronic treatment with MK-886 prevented this rise in MABP. (4) Aortic rings with or without endothelium were suspended in organ baths for recording isometric changes in response to noradrenaline. Pretreatment with either MK-886 (10 microm), the CysLT1 receptor antagonist MK571 (1 microm) or the dual CysLT1/CysLT2 receptor antagonist BAY-u9773 (0.1 microm) reduced (P<0.05) noradrenaline-induced contractions in intact aortic rings from l-NAME-treated rats only. (5) Noradrenaline (0.3 microm) induced a two-fold increase in cysteinyl leukotriene (CysLT) release (measured by enzyme immunoassay) in intact aortic rings from l-NAME-treated rats only. (6) These data suggested (1) a role for the 5-lipoxygenase pathway in the regulation of blood pressure in l-NAME-treated rats and (2) the involvement of endothelial CysLTs in noradrenaline-induced contraction in aorta from l-NAME-treated rats.
Collapse
|
11
|
Köller M, Wick M, Muhr G. Decreased leukotriene release from neutrophils after severe trauma: role of immature cells. Inflammation 2001; 25:53-9. [PMID: 11293666 DOI: 10.1023/a:1007027712387] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Polymorphonuclear granulocytes (PMN) play a key role in host defense against microbial infections. After severe trauma PMN show cellular dysfunctions including chemotactic migration, phagocytosis, and bacterial killing. In these settings the contribution of the cellular maturation stage compared to functional activities has not been investigated. Polymorphonuclear granulocytes are potent producers of lipid mediators via the 5-lipoxygenase (5-LO) pathway (leukotrienes, LTs) which exert important proinflammatory and immunoregulatory activities. We analyzed leukotriene generation from PMN-fractions (N = 23) of 15 polytrauma patients in comparison to 17 healthy donor cell fractions and correlated this lipid mediator release to the hematopoietic maturation stage of respective PMN. Polymorphonuclear granulocytes were isolated from EDTA-anticoagulated peripheral blood employing a one step procedure based on a discontinuous double Ficoll-gradient. Cells (5 x 10(6)/500 microl phosphate-buffered saline) were stimulated for 20 min at 37 degrees C with 1 microM Ca-ionophor A23187 in the presence of 1 mM Ca++ and 0.5 mM Mg++. Leukotrienes were analyzed by reversed-phase HPLC. Expression of 5-lipoxygenase (5-LO) was additionally determined by Western blot. Maturation stage of PMN was quantitated by Pappenheim-staining of cell smears. After polytrauma the generation of leukotrienes from PMN was individually diminished. Synthesis of enzymatically formed metabolites (LTB4, OH-LTB4 and COOH-LTB4) was concomitantly reduced. The decresaed leukotriene synthesis strongly correlated (r2 = 0.907, P < 0.0001) to the occurrence of immature PMN (mostly band cells). The expression of 5-lipoxygenase in PMN fractions consisting mainly of band cells was decreased. Our results provide evidence that posttraumatic granulocyte dysfunction is partly due to immature functional cell capacities.
Collapse
Affiliation(s)
- M Köller
- Department of Surgery, Surgical Research, BG Kliniken Bergmannsheil, Bochum, Germany
| | | | | |
Collapse
|
12
|
Chauvet P, Bienvenu JG, Théorêt JF, Latour JG, Merhi Y. Inhibition of platelet-neutrophil interactions by Fucoidan reduces adhesion and vasoconstriction after acute arterial injury by angioplasty in pigs. J Cardiovasc Pharmacol 1999; 34:597-603. [PMID: 10511137 DOI: 10.1097/00005344-199910000-00018] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The selectin family of cell-adhesion molecules contributes to the interactions of leukocytes and platelets at the site of vascular injury. Such interactions enhance inflammatory reactions and thrombus formation during the arterial response to injury. In this study, we investigated the effects of a selectin inhibitor (Fucoidan) on platelet and neutrophil interactions after arterial injury produced by angioplasty in pigs. [51Cr]-platelet deposition and [111In]-neutrophil adhesion were quantified on intact, mildly, and deeply injured carotid arterial segments, produced by balloon dilation in control (saline, n = 7) and Fucoidan-treated (i.v.; 1 mg/kg, n = 6; 5 mg/kg, n = 5) pigs. In the control group, platelet deposition (x10(6)/cm2) was influenced by the severity of injury and increased significantly (p < 0.05) from 0.06+/-0.06 on intact endothelium to 3.8+/-0.6 and 33.6+/-4.9 on mildly and deeply injured segments, respectively. Fucoidan, 1 mg/kg, had no significant effect, although doses of 5 mg/kg reduced platelet deposition by 73% on deeply injured segments. The level of neutrophil adhesion (x10(3)/cm2) was also influenced by the severity of injury: it increased in the control group from 8.8+/-2.5 on intact endothelium to 226.6+/-45.5 and 397.4+/-61.3 on mildly and deeply injured arterial segments, respectively (p < 0.05). Again, 1 mg/kg Fucoidan had no effect, although doses of 5 mg/kg reduced neutrophil adhesion by 92% and by 84% on mildly and deeply injured segments, respectively. The effects of Fucoidan were associated with a 51% decrease in the vasoconstrictive response at the site of arterial injury. However, Fucoidan had no significant effect on either platelet aggregation or activated clotting time (ACT). In the in vitro perfusion experiments, Fucoidan inhibited both isolated platelet, and neutrophil, adhesion to damaged arterial surfaces. This inhibition was more pronounced in experiments using mixed cell preparations, indicating that Fucoidan interferes with platelet and neutrophil interactions. These results highlight the importance of selectins in the acute physiopathologic reactions related to platelet-neutrophil interactions after arterial injury.
Collapse
Affiliation(s)
- P Chauvet
- Laboratory of Experimental Pathology, Montreal Heart Institute and the University of Montreal, Quebec, Canada
| | | | | | | | | |
Collapse
|